News and Announcements
Nico.lab Fundraising Ahead of IPO for Stroke Treatment Technology
- Published June 12, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Nico.lab’s technology enables the fast and accurate image analysis to allow for quick decisions to be made by Doctors.
- The company is planning to raise funds before their IPO in February 2019.
- The funds they plan on raising will help accelerate the strategy to bring their technology, StrokeViewer, to the market in Australia and Europe.
Nico.lab, established in 2015, is planning to raise funds before their IPO in February 2019. The funds they plan on raising will help accelerate the strategy to bring their technology, StrokeViewer, to the market in Australia and Europe. Their technology aims to reduce the treatment time for stroke patients. It will also fund the development of the AI algorithm required for effective stroke detection over the next 12 months. The IPO Funds in February 2019 will focus on the technology rollout in the United States.
Nico.lab’s technology enables the fast and accurate image analysis to allow for quick decisions to be made by Doctors. It will reduce treatment time from hours to minutes. The technology has all four biomarkers required for accurate stroke detection. Within 3 minutes the StrokeViewer informs doctors with a biomarker report and image they can view on any device. Every hour that doctors can treat a stroke victim, the number of patients who recover without significant complications increase by 15%.
The CE certified technology uses artificial intelligence and machine learning to improve performance continually. Nico.lab has had 15 hospitals in the Netherlands sign up to use the technology. Peak Asset Management, an advisory firm, is planning to raise $2.3m, with the shares priced at 15¢, for Nico.lab before the IPO next year.
About Nico.Lab
Nico.lab’s StrokeViewer® uses AI to reduces time-to-decision for stroke patients to 3 minutes compared to the current manual protocol which can take hours.
StrokeViewer® has been approved for roll-out by 15 hospitals.
The company has an exceptional management team and board, with over €4M and years of research spent to date.
Investors have an opportunity at a compelling €4.5M pre-money valuation, ahead of an ASX listing in 1Q18.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
